Non-invasive Point-Of-Care Hemoglobin Testing In An Obstetric Population
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pregnancy Anemia
- Sponsor
- Beth Israel Deaconess Medical Center
- Enrollment
- 124
- Locations
- 1
- Primary Endpoint
- Hemoglobin (g /dL) Accuracy of Masimo RAD 67
- Status
- Completed
- Last Updated
- last month
Overview
Brief Summary
Anemia is common during pregnancy due to increased metabolic rate and normal physiologic changes associated with pregnancy. Anemia during pregnancy has been associated with increased of adverse outcomes during delivery and the postpartum period. Currently, it is recommended to screen for anemia at three pre-specified points during routine prenatal care, typically 3 months apart. This screening method may miss patients who develop anemia between these intervals and lead to a delay in diagnosis and treatment.
MasimoTM has developed a non-invasive device that can detect anemia without a blood draw. This device has not been extensively studied in pregnant patients. The aim of this study is to determine the agreement in hemoglobin readings between the non-invasive device and the standard of care blood draws in pregnant patients.
Detailed Description
This is a prospective observational study of a non-invasive hemoglobin measurement device in a pregnant patient population. The device is FDA approved for use in adults, children, and neonates. The current standard of care for anemia screening during pregnancy involves performing invasive venipuncture at two separate visits throughout the course of the pregnancy. The purpose of this research study is to compare the device performance with the gold standard hemoglobin measurement (venipuncture) when patients receive routine hemoglobin measurement during the course of their prenatal care. The research team will approach pregnant patients who are presenting for prenatal care at Beth Israel Deaconess Medical Center, including the Labor and Delivery Triage Unit. The research team also will approach patients during an antepartum or postpartum admission. The research team will use the Masimo Rad-67 handheld co-oximeter which has a reusable finger-tip sensor that enables spot-check monitoring measurements of both oxygen saturation and non-invasive hemoglobin measurement. Study personnel will receive training on proper device use and cleaning by the local Masimo support team. At the time of a blood draw, the research team will place the pulse oximeter on the participant's finger. The devices requires 1-3 minutes for an accurate measurement. After the measurement is complete, the participant will be asked 2 questions on their satisfaction and comfortability with the device and 1 question regarding their skin tone using a validated skin tone scale.
Investigators
Ethan Litman
Clinical Fellow in Obstetrics, Gynecology and Reproductive Biology
Beth Israel Deaconess Medical Center
Eligibility Criteria
Inclusion Criteria
- •Pregnant or postpartum;
- •Age ≥18 years old;
- •Undergoing phlebotomy for clinical purpose
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Hemoglobin (g /dL) Accuracy of Masimo RAD 67
Time Frame: At time of phlebotomy
Performance will be determined by calculating mean difference and repeatability analysis through the comparison of the hemoglobin values obtained from Masimo RAD67 to the hemoglobin values obtained from a reference phlebotomy sample collected at the same time.
Secondary Outcomes
- Hemoglobin (g /dL) Accuracy of Masimo RAD 67 stratified by skin tone(At time of phlebotomy)
- Hemoglobin (g /dL) Accuracy of Masimo RAD 67 stratified by gestational age(At time of phlebotomy)